ReviewInternational journal of nanomedicine2026
Nanomedicine-Enabled/Augmented Cell Autophagy to Mitigate and Boycott the Development and Progression of Atherosclerotic Plaque.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a chronic, inflammatory and systemic disease that seriously threatens human health and is the main factor leading to the morbidity and mortality of cardiovascular diseases. Autophagy has been regarded as an effective therapeutic strategy for AS, which can represent an important self-protecting intracellular system that can delivery and capture destroyed organelles and unnecessary proteins to lysosome for degradation. Thanks to the fast progress of nanotechnology, nanomedicine is widely used to enable, potentiate, and augment autophagy for promoting the AS-therapeutic efficacy and specificity. This review focuses on discussing the latest advances in this emerging field, with a particular emphasis on the nanomedicine-enabled/augmented autophagy approach for supporting the construction of next-generation nanomedicines to effectively trigger autophagy in the treatment of AS. Particularly, the biocompatibility and biosafety of engineering nanomedicine, the current challenges and futural prospects are also summarized in this comprehensive review, aiming to accelerate future clinical translation of this burgeoning field. It is highly anticipated that future clinical transformation of nanomedicine can be achieved by inducing autophagic activation based on bioactive nanomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.